Skip to main content
TipRanks
Go Ultimate75% OFF

Corline Biomedical AB (CLBIO) AI Stock Analysis

0 Followers
SE:CLBIO

Corline Biomedical AB

(Nasdaq OMX AB:CLBIO)

Select Model
Rating:42Neutral
Price Target:SEK 13.50â–¼(-3.57% Downside)
Action:upgraded
Date:08/27/26

The score is held back primarily by weak financial performance: Corline Biomedical is loss-making, burns roughly SEK 15m of cash per year, has negative gross profit and reports small, erratic milestone-based revenue, all of which point to continued reliance on external funding and dilution risk. The main strength is a debt-free balance sheet with ~87% equity-to-assets, alongside improving TTM revenue (+25%), a narrower net loss and lower capital spending. Technicals add little support, with the price below all major moving averages and RSI near oversold levels. Valuation offers no cushion given negative earnings and no dividend. Earnings call and corporate events were excluded due to missing data, with their weight redistributed across the remaining components.

Positive Factors
Debt-free balance sheetA debt-free balance sheet reduces leverage pressure and preserves financial flexibility while the company develops and commercializes its technologies. The sizable equity base relative to assets provides resilience and avoids interest obligations, although improved profitability remains necessary to build shareholder value.
Negative Factors
Persistent operating lossesContinued losses show that revenue growth has not yet translated into a sustainable economic model. Persistent negative margins can consume capital, limit internally funded investment, and make the company more dependent on stronger commercialization or future external financing to support its development plans.

Corline Biomedical AB (CLBIO) vs. iShares MSCI Sweden ETF (EWD)

-40%-30%-20%-10%0%10%20%30%SE:CLBIO-26.32%EWD+8.63%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 365.86M
Dividend Yield
―
Average Volume (3M)
16.32K
Price to Earnings (P/E)
-26.3
Beta (1Y)
0.47
Revenue Growth
77.77%
EPS Growth
47.65%
Country
Sweden
Employees
14
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Corline Biomedical AB Business Overview & Revenue Model

Company Description

Corline Biomedical AB is a company dedicated to the creation, production, and distribution of heparin-based solutions. These solutions are specifically engineered to enhance outcomes in kidney transplantation, cellular therapies, and regenerative med...

How the Company Makes Money

Corline Biomedical makes money primarily by commercializing its blood-compatible biomaterial and surface-technology solutions through product sales and B2B collaborations. Key revenue streams typically include: (1) Sales of proprietary products/consu...

Corline Biomedical AB Financial Statement Overview

Summary

Corline Biomedical shows the typical early-stage biotech profile: a debt-free balance sheet (equity of about SEK 99.0m against SEK 114.2m of assets, ~87% equity-to-assets) funding a business that is not yet profitable or cash-generative. The income statement is weak (score 27) with small, milestone-driven revenue that has swung from SEK 25.0m in 2023 to SEK 7.7m in 2025, a TTM net loss of SEK 12.3m on SEK 12.4m of revenue, and negative gross profit. Cash flow is weaker still (score 20), with TTM operating and free cash flow of roughly negative SEK 14.4m and SEK 14.8m and negative free cash flow in every year shown. The balance sheet (score 72) offsets some of this risk, but equity is being eroded by losses and sustained through shareholder funding, implying recurring dilution risk. Encouraging signs include ~25% TTM revenue growth, a narrower loss versus 2024 and 2025, and sharply reduced capital spending.

Income Statement

27Negative

Balance Sheet

72Positive

Cash Flow

20Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue12.39M7.65M9.78M25.03M23.55M7.06M
Gross Profit4.87M-14.21M13.44M28.38M22.73M9.10M
EBITDA-12.23M-14.12M-23.07M-1.69M2.38M-6.88M
Net Income-12.32M-14.71M-23.19M-1.81M2.33M-6.92M
Balance Sheet
Total Assets114.18M98.58M94.76M100.11M101.78M101.66M
Cash, Cash Equivalents and Short-Term Investments32.99M20.56M17.67M17.01M26.21M41.63M
Total Debt000000
Total Liabilities15.18M4.82M7.85M6.79M7.19M9.43M
Stockholders Equity99.00M93.76M86.91M93.32M94.59M92.23M
Cash Flow
Free Cash Flow-14.85M-17.74M-16.14M-9.73M-15.45M-14.45M
Operating Cash Flow-14.44M-17.69M-8.64M886.00K-6.45M-4.83M
Investing Cash Flow-750.00K-982.00K-7.50M-10.62M-9.00M-9.56M
Financing Cash Flow39.87M21.56M16.79M537.00K26.00K47.13M

Corline Biomedical AB Technical Analysis

Technical Analysis SentimentNegative
Last Price14.00

Price Trends

50DMA14.10Negative
100DMA15.72Negative
200DMA16.19Negative

Market Momentum

MACD0.01Negative
RSI49.99Neutral
STOCH60.71Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CLBIO, the sentiment is Negative. The current price of 14.00 is above the 20-day moving average (MA) of 13.84, below the 50-day MA of 14.10, and below the 200-day MA of 16.19, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 49.99 is Neutral, neither overbought nor oversold. The STOCH value of 60.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:CLBIO.

Corline Biomedical AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:CLBIO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:HNSASE:HNSA60NeutralSEK 4.82B-5.71――68.88%10.63%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:NXTCLSE:NXTCL46NeutralSEK 30.33M-0.57-81.23%―-4.02%35.86%
SE:SPAGOSE:SPAGO42NeutralSEK 33.21M-1.03-87.37%―-97.52%31.31%
SE:CLBIOSE:CLBIO42NeutralSEK 375.01M-26.29――77.77%47.65%
SE:FLUOSE:FLUO40UnderperformSEK 482.30M-6.55―――-23.57%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%SE:CLBIOSE:HNSASE:NXTCLSE:SPAGOSE:BIOWKSSE:FLUODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:CLBIO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:CLBIOCorline Biomedical AB14.00-5.05-26.51%
SE:HNSAHansa Biopharma45.1416.4057.06%
SE:NXTCLNextCell Pharma AB0.22-0.53-71.07%
SE:SPAGOSpago Nanomedical AB0.04-0.05-56.84%
SE:BIOWKSBio-Works Technologies AB2.910.3915.48%
SE:FLUOFluoGuide A/S29.50-8.50-22.37%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 27, 2026